TreeENT completes 100 million yuan Pre-B round financing to create a new model f

Recently, ENT specialty medical institution Renshu Medical announced the completion of a 100 million yuan pre-B round financing, led by Qianji Capital with follow-on investment from existing shareholder Fidelity Capital. It is reported that Renshu Medical has previously received investments from renowned capital firms including China Growth Capital, with cumulative financing reaching hundreds of millions of yuan. After six years of development, Renshu Medical has gradually transformed its capital advantages into scale and first-mover advantages, expanding nationwide. Following Hangzhou and Shenzhen, Renshu Medical will establish chain clinics and specialty hospitals in Shanghai and Guangzhou this year, providing high-quality medical services to more patients.

TreeENT Focuses on Niche Specialty Services

In today's healthcare system, private medical institutions must possess differentiated service features and professional core competencies to gain patient and market recognition. Renshu Medical's successful pre-B round financing is closely tied to its specialty services that meet market demands.

In recent years, the niche specialty market has emerged, where refined services hold significant appeal in addressing patient healthcare needs. Renshu Medical has precisely targeted the ENT specialty field, investing substantial effort and resources to continuously strengthen its discipline development and treatment standards, achieving precision in medical services.

As an ENT specialty medical institution, Renshu Medical implements personalized triage based on patients' varying symptoms. For pediatric adenoid hypertrophy, it provides internationally-advanced minimally invasive surgical treatment, while offering non-invasive CPAP therapy (the gold standard) for sleep apnea. Tailored treatment plans are developed according to each patient's condition and needs, maximizing precision diagnosis and refined service delivery.

Notably, Renshu Medical is the first outpatient and day surgery center in China to obtain DNV international certification. While public hospitals typically require 3-7 days for surgery and hospitalization, ENT procedures are particularly suitable for day surgery - allowing same-day operation and discharge - meeting modern patients' need for efficient treatment while ensuring recovery.

Renshu Medical has assembled a high-caliber expert team including overseas-educated PhDs/Masters and experienced chief physicians from top-tier hospitals. Its distinctive "1-minute expert appointment, 1-hour consultation with testing, 1-day surgery discharge" process significantly improves utilization of premium medical resources, earning trust from both physicians and patients.

The day surgery model has gained strong market recognition and government policy support. The successful 100 million yuan Pre-B round financing further validates Renshu Medical's advantages and potential in niche specialty markets.

ENT specialty care is poised for major development in the coming decade. Post-pandemic health awareness has increased demand for specialized treatment of nuanced conditions. Through rigorous market research, Renshu Medical has committed to the high-incidence ENT field, establishing professional leadership through multiple funding rounds.

Despite being in the market cultivation phase, Renshu Medical has differentiated itself through clinical excellence and efficient services. Following successful operations in Hangzhou and Shenzhen, its Shanghai center will launch soon with Guangzhou project already initiated.

Currently, ENT diseases show high prevalence but low treatment rates among China's population aged 20+. Considering China's ENT disease trends and the maturation of its diagnosis and treatment system, the ENT specialty sector is expected to witness significant growth opportunities in the next decade. This presents a major development opportunity for specialized medical institutions like Renshu Medical that focus on ENT as their core competency. Moving forward, Renshu Medical will leverage its professional medical standards and specialized precision services to achieve a win-win-win scenario for patients, the platform, and investors.

About Qianji Capital

As the lead investor in this funding round, Qianji Capital was established in 2010 and is one of China's earliest professional funds dedicated to healthcare and life sciences investments. It is committed to promoting transformation and innovation in China's medical industry. Currently managing six healthcare funds in both USD and RMB, its limited partners include Asian sovereign wealth funds, government agencies, and large domestic and international insurance companies and financial institutions.

About Fidelity Capital

As Renshu Medical's long-term investment partner, Fidelity Capital is a global proprietary investment institution backed by the US-based Fidelity group. With its unique capital attributes, Fidelity Capital can flexibly deploy funds to support innovative companies in disrupting or leading markets, helping entrepreneurs realize their ambitions. Healthcare services represent one of Fidelity Capital's key focus areas, with nearly a decade of dedicated portfolio management and post-investment support in China's healthcare sector.